Thromb Haemost 1997; 78(01): 271-275
DOI: 10.1055/s-0038-1657538
Platelet membrane glycoproteins
Schattauer GmbH Stuttgart

Activation of ADP Receptors and Platelet Function

Christian Gachet
INSERM U.311, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg, France
,
Béatrice Hechlel
INSERM U.311, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg, France
,
Catherine Léon
INSERM U.311, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg, France
,
Catherine Vial
INSERM U.311, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg, France
,
Claude Leray
INSERM U.311, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg, France
,
Philippe Ohlmann
INSERM U.311, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg, France
,
Jean-Pierre Cazenave
INSERM U.311, Etablissement de Transfusion Sanguine de Strasbourg, Strasbourg, France
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

 
  • References

  • 1 Hellem AJ. The adhesiveness of human blood platelets in vitro. Scand J Clin Lab Invest 1960; 12: 001-117
  • 2 Ollgaard E. Macroscopic studies of platelet aggregation: nature of an aggregating factor in red blood cells and platelets. Thromb Diath Haemorrh 1961; 06: 86-97
  • 3 Gaardner A, Jonsen J, Laland S, Hellem A, Owren PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-532
  • 4 Burnstock G. A basis for distinguishing two types of purinergic receptors. In: Cell Membrane Receptors for Drugs and Hormones : a Multidisciplinary Approach. Eds Bolis L, and Straub RN. Raven Press; New York: 1978. pp 107-118
  • 5 Dubyac GR, El MoatassimC. Signal transduction via P2- purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol 1993; 265: C577-C606
  • 6 Abbracchio MP, Burnstock G. Purinoceptors: are there families of P2X and P2Y purinoceptors?. Pharmacol Ther 1994; 64: 445-475
  • 7 Burnstock G, King BF. The numbering of cloned P2 purinoceptors. Drug Dev Res 1996; 38: 67-71
  • 8 Reimers HJ. Adenine nucleotides in blood platelets. In: Longenecker GL. (ed) The Platelets: Physiology and Pharmacology. Academic Press; Orlando: 1985. pp 85-98
  • 9 Born GVR. Adenosine diphosphate as a mediator of platelet aggregation in vivo: an editorial point of view. Circulation 1985; 72: 741-742
  • 10 Maffrand JP, Bernat A, Delebassée D, Defreyn G, Cazenave JP, Gordon JL. ADP plays a key role in thrombogenesis in rats. Thromb Haemostas 1988; 59: 225-230
  • 11 Herbert JM, Frehel D, Vallée E, Kieffer G, Gouy D, Berger Y, Necciari J, Defreyn G, Maffrand JP. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: 180-198
  • 12 Humphries RG, Robertson MJ, Leff P. A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol Sci 1995; 16: 179-181
  • 13 Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannuci PM. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood 1992; 80: 2787-2796
  • 14 Nurden P, Savi P, Heilmann E, Bihour C, Herbert JM, Maffrand JP, Nurden A. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. J Clin Invest 1995; 95: 1612-1622
  • 15 Gachet C, Cattaneo M, Ohlmann P, Lecchi A, Hechler B, Chevalier J, Cassel D, Mannucci PM, Cazenave JP. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 1995; 91: 434-444
  • 16 Cattaneo M, Lombardi R, Zighetti ML, Gachet C, Ohlmann P, Cazenave JP, Mannucci PM. Deficiency of [33P]2MeSADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Thromb Haemostas. 1997 (In press)
  • 17 Hourani SMO, Hall DA. Receptors for ADP on human blood platelets. Trends Pharmacol Sci 1994; 15: 103-108
  • 18 Gachet C, Hechler B, Léon C, Vial C, Ohlmann P, Cazenave JP. Purinergic receptors on blood platelets. Platelets 1996; 07: 261-267
  • 19 Mills DCB. ADP receptors on platelets. Thromb Haemostas 1996; 76: 835-856
  • 20 MacFarlane DE. Agonists and receptors: adenosine diphosphate. In: Platelet Responses and Metabolism. Holmsen H. Ed. CRC Press; Boca Raton, Florida: 1987. pp 19-36
  • 21 Mustard JF, Perry DW, Kinlough-Rathbone RL, Packham MA. Factors responsible for ADP induced release reaction of human platelets. Am J Physiol 1975; 228: 1857-1865
  • 22 Packham MA, Bryant NL, Guccione MA, Kinlough-Rathbone RL, Mustard JF. Effect of concentration of Ca2+ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemostas 1989; 62: 968-976
  • 23 Heermskerk JWM, Sage SO. Calcium signalling in platelets and other cells. Platelets 1994; 05: 295-316
  • 24 Sage SO, Rink TJ. Kinetic differences between thrombin induced and ADP induced calcium influx and release from internal stores in fura-2 loaded human platelets. Biochem Biophys Res Commun 1986; 136: 1124-1129
  • 25 Mahaut-Smith MP, Sage SO, Rink TJ. Rapid ADP evoked currents in human platelets recorded with the nystatin permeabilized patch technique. J Biol Chem 1992; 267: 3060-3065
  • 26 MacKenzie AB, Mahaut-Smith MP, Sage SO. Activation of receptor operated channels via P2X1 not P2T purinoceptors in human platelets. J Biol Chem 1996; 271: 2879-2881
  • 27 Haslam RJ. Interactions of the pharmacological receptors of blood platelets with adenylate cyclase. Ser Haematol 1973; 06: 333-350
  • 28 Cooper DMF, Rodbell M. ADP is a potent inhibitor of human platelet plasma membrane adenylate cyclase. Nature 1979; 282: 517-518
  • 29 Mellwig KP, Jakobs KH. Inhibition of adenylate cyclase by ADP. Thromb Res 1980; 18: 7-17
  • 30 Gachet C, Cazenave JP, Ohlmann P, Hilf G, Wieland T, Jakobs KH. ADP receptor induced activation of guanine nucleotide binding proteins in human platelet membranes. Eur J Biochem 1992; 207: 259-263
  • 31 Ohlmann P, Laugwitz KL, Spicher K, Nurnberg K, Schultz G, Cazenave JP, Gachet C. The human platelet ADP receptor activates Gi2 proteins. Biochem J 1995; 312: 775-779
  • 32 Rittenhouse SE. Phosphoinositide 3-kinase activation and platelet function. Blood 1996; 88: 4401-4414
  • 33 Gachet C, Payrastre B, Guinebault C, Trumel C, Ohlmann P, Mauco G, Cazenave JP, Plantavid M, Chap H. Reversible translocation of phosphoinositide 3-kinase to the cytoskeleton of ADP aggregated human platelets occurs independently of Rho and without synthesis of phosphatidylinositol (3,4)- biphosphate. J Biol Chem 1997; 272: 4850-4854
  • 34 Zhang J, Zhang J, Benovic JL, Sugai M, Wetzker R, Gout I, Rittenhouse SE. Sequestration of a G protein bg subunit or ADP ribosylation of rho can inhibit thrombin induced activation of platelet phosphoinositide 3-kinase. J Biol Chem 1995; 270: 6589-6594
  • 35 Cusack NJ, Hourani SMO. Effects of Rp and Sp diastereoisomers of adenosine 5’-0-(l-thiodiphosphate) on human platelets. BrJ Pharmacol 1981; 73: 409-412
  • 36 Cusack NJ, Hourani SMO. Partial agonist behavior of adenosine 5’-0-(2-thiodiphosphate) on human platelets. Br J Pharmacol 1981; 73: 405-408
  • 37 Hourani SMO, Hall DA, Nieman CJ. Effects of the P2- purinoceptor antagonist, suramin, on human. platelet aggregation induced by adenosine 5’-diphosphate. Br J Pharmacol 1992; 105: 453-457
  • 38 Hall DA, Hourani SMO. Effects of suramin on increases in cytosolic calcium and on inhibition of adenylate cyclase induced by adenosine 5’-diphosphate in human platelets. Biochem Pharmacol 1994; 47: 1013-1018
  • 39 Windscheif U, Radsiwon P, Breddin HK, Bäumert HG, Lambrecht G, Mutschler E. Two different inhibitory effects of pyridoxalphosphate-6-azophenyl-2’,4’-disulfonic acid on adenosine diphosphate induced human platelet aggregation. Arzneimittelforschung 1995; 45: 994-997
  • 40 Hall DA, Hourani SMO. Effects of analogues of adenine nucleotides on increases in intracellular calcium mediated by P2T-purinoceptors on human blood platelets. Br J Pharmacol 1993; 108: 728-733
  • 41 Hourani SMO, Welford LA, Cusack NJ. Effects of 2- Methylthioadenosine 5’-b,g-Methylenetriphosphonate and 2- Ethylthioadenosine 5’-monophosphate on human platelet activation induced by adenosine 5’-diphosphate. Drug Dev Res 1996; 38: 12-23
  • 42 Mills DC, Puri R, Minniti C, Grana G, Freedmann MD, Colman RF, Colman RW. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arteriosclerosis Thrombos 1992; 12: 430-436
  • 43 Savi P, Laplace MCL, Maffrand JP, Herbert JM. Binding of [3H]-2 Methyl-thio-ADP to rat platelets. Effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994; 269: 772-777
  • 44 Pearce PH, Wright JM, Egan CM, Scrutton MC. Interaction of human blood platelets with the 2’, 3’-dialdehyde and 2’, 3’- dialcohol derivatives of adenosine 5’-diphosphate and adenosine 5’-triphosphate. Eur J Biochem 1978; 88: 543-554
  • 45 Adler JR, Handin RI. Solubilization and characterization of a platelet membrane ADP binding protein. J Biol Chem 1979; 254: 3866-3872
  • 46 Colman RW. Aggregin: a platelet ADP receptor that mediates activation. Faseb J 1990; 4: 1425-1435
  • 47 Cristalli G, Mills DC. Identification of a receptor for ADP on blood platelets by photoaffinity labelling. Biochem J 1993; 291: 875-881
  • 48 Gachet C, Cazenave JP, Ohlmann P, Bouloux C, Defreyn G, Driot F, Maffrand JP. The thienopyridine ticlopidine selectively prevents the inhibition effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE. Biochem Pharmacol 1990; 40: 2683-2687
  • 49 Defreyn G, Gachet C, Savi P, Driot F, Cazenave JP, Maffrand JP. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE, activated platelet adenylate cyclase in rats and rabbits. Thromb Haemostas 1991; 65: 186-190
  • 50 Gachet C, Savi P, Ohlmann P, Maffrand JP, Jakobs KH, Cazenave JP. ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes. An effect selectively blocked by the thienopyridine clopidogrel. Thromb Haemostas 1992; 68: 79-83
  • 51 Savi P, Laplace MCL, Herbert JM. Evidence for the existence of two different ADP binding sites on rat platelets. Thromb Res 1994; 76: 157-169
  • 52 Sanderson HM, Heptinstall S, Vickers J, Losche W. Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood. Blood Coag Fibrinol 1996; 07: 245-248
  • 53 Ayyanathan K, Webb TE, Sandhu AK, Athwal RS, Barnard EA, Kunapuli SP. Cloning and chromosomal localization of the human P2Y1 purinoceptor. Biochem Biophys Res Comm 1996; 218: 783-788
  • 54 Webb TE, Simon J, Krishek BJ, Bateson AN, Smart TG, King BF, Bumstock G, Barnard EA. Cloning and functional expression of a brain G protein coupled ATP receptor. FEBS Lett 1993; 324: 219-225
  • 55 Akbar GKM, Dasari VR, Webb TE, Ayyanathan K, Pillarisetti K, Sandhu AK, Athwal RS, Daniel JL, Ashby B, Barnard EA, Kunapuli SP. Molecular cloning of a novel P2 purinoceptor from human erythroleukemia cells. J Biol Chem 1996; 271: 18363-18367
  • 56 Léon C, Vial C, Cazenave JP, Gachet C. Cloning and sequencing of a human cDNA encoding endothelial P2Y1 purinoceptor. Gene 1996; 171: 295-297
  • 57 Léon C, Hechler B, Vial C, Leray C, Cazenave JP, Gachet C. The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 1997; 403: 26-30
  • 58 Vial C, Hechler B, Léon C, Cazenave JP, Gachet C. Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines. Thromb Haemostas. 1996. (submitted)